Global Inhalation Anesthesia Market is Gaining Rapid Traction with Industry Leader Sandoz Launching Desflurane Liquid for Inhalation, and the first generic of Suprane in the U.S.
Inhalation anesthetics are used for
induction and maintenance of general anesthesia in the operating room. These
anesthetics drugs include insoflurane, desflurane, halothane, nitrous oxide,
and sevoflurane. These anesthesia drugs induce loss of sensation or awareness
and are typically used during surgeries to prevent pain. The type and degree of
these drugs may vary according to surgeries and patient condition. The
inhalation agents used in modern practice include desflurane, fluorinated
ethers isoflurane, sevoflurane, and gas nitrous oxide (N2O). Furthermore, noble
gas such as xenon has significant anesthetic properties although its high
production cost is reducing its adoption.
Increasing prevalence of cancer,
spinal, and respiratory diseases are expected to drive growth of the global
inhalation anesthesia market during the forecast period. According to the World
Health Organization (WHO), in 2018, around 9.6 million people died because of
cancer. According to the same source, around 17.9 million people die each year
due to cardiovascular disease (CVD). Inhalable anesthesia drugs offer an
efficient solution for anesthesia during surgeries. Hence, these factors are
expected to drive growth of the global
inhalation anesthesia market. Furthermore, increasing number of emergency
cases are expected to propel the global inhalation anesthesia market growth in
the near future. According to the Centers for Disease Control and Prevention
(CDC), around 139 million people make visits to the emergency department, of which
40 million are injury-related.
However, stringent regulations on the
use of these drugs are expected to hinder the global inhalation anesthesia
market growth in the near future. Among regions, North America is expected to
witness significant growth in the global inhalation anesthesia market. This is
owing to increasing prevalence of various chronic diseases and the presence of
robust healthcare infrastructure in the region. According to the National
Cancer Institute, there around 442.4 new cases of cancer per 100,000 men and
women and 158.3 per 100,000 deaths per year in the U.S. Furthermore, Asia
Pacific is expected to register a robust growth rate, owing to rising numbers
of surgeries in the region.
Major companies operating in the
global inhalational anesthesia market are Baxter, Fresenius Kabi, AbbVie,
Jiangsu Hengrui Medicine, Piramal Enterprises, and Halocarbon Products.
For instance, in January 2019,
Sandoz, a subsidiary of Novartis, launched Desflurane Liquid for Inhalation,
the first generic of Suprane in the U.S.
Comments
Post a Comment